Moody's A1 for Daman is, on PureHealth's account, the highest insurer rating in the GCC. It is also single-A, and that is the ceiling a UAE health insurance deal is now read against.
On 2 July 2026 PureHealth announced that Moody's had assigned its insurance vertical, The National Insurance Company – Daman, an A1 Insurance Financial Strength Rating with a stable outlook, which PureHealth describes as the highest Moody's IFSR for a UAE insurer and the highest across the GCC among life, P&C and reinsurance companies. On Moody's own scale that ceiling sits at the upper end of single-A. The rating was earned on a book where P&C was still about 1.5% of H1 2026 premium, and the five drivers Moody's named are the diligence list for any UAE health insurer, TPA or managed-care target.
What a board member needs before the next meeting on this.
- The regional ceiling is the upper end of single-A. PureHealth describes Daman's A1 as the highest IFSR Moody's has assigned to a UAE insurer and the highest across the GCC among life, P&C and reinsurance companies. Moody's scale defines A as upper-medium grade with low credit risk, and the modifier 1 as the higher end of that category.
- The rating rests on a book where P&C is still small. PureHealth's H1 2026 release reported approximately AED 83 million of P&C premium against AED 5.5 billion of gross written premium for the insurance vertical. On our arithmetic that is about 1.5%. The diversification Moody's noted is expected over time.
- The five drivers are the diligence scope. Moody's highlighted leading market position, strong profitability, resilient capital adequacy, high-quality reinsurance support and a liquid investment portfolio, according to PureHealth. Each can be tested on a private target's own accounts, treaties and investment schedules.
- It is a credit reference, not a pricing comp. An IFSR is an opinion of an insurer's ability to pay senior policyholder claims on time. It says nothing about a multiple or a cost of equity, and it sits on one entity inside a listed group.
On 2 July 2026 PureHealth Holding PJSC (ADX: PUREHEALTH) announced that its insurance vertical, The National Insurance Company – Daman, had been assigned an A1 Insurance Financial Strength Rating by Moody's Ratings with a stable outlook (PureHealth release, 2 July 2026).
PureHealth's H1 2026 results release of 31 July dates the assignment to June (PureHealth H1 2026 release, 31 July 2026). The 2 July release describes A1 as the highest IFSR Moody's has assigned to a UAE insurance company and the highest across the GCC among life, property and casualty, and reinsurance companies.
That claim is PureHealth's, reporting Moody's. Read as a headline, it says Daman is the strongest insurer in the region. Read as a benchmark, it tells anyone buying, selling or lending against a UAE health insurance business where the top of the regional scale sits and what Moody's credited to put an insurer there.
The top of the GCC scale is upper-medium grade
Moody's defines an Insurance Financial Strength Rating as an opinion of an insurer's ability to punctually pay senior policyholder claims and obligations, and it reflects the expected financial loss in the event of default.
On its global long-term scale, obligations rated A are judged upper-medium grade and subject to low credit risk, Aa is high quality with very low credit risk, and the modifier 1 places a rating at the higher end of its category (Moody's Rating Symbols and Definitions).
Set PureHealth's claim beside those definitions and the regional ceiling becomes exact: on PureHealth's account of Moody's, no life, P&C or reinsurance company in the GCC holds a Moody's IFSR above the upper end of single-A. A seller who describes a UAE insurance target as strongly rated is now compared, in every informed buyer's mind, with a public A1 on the market leader. Where the target holds no Moody's rating at all, the comparison still happens; it moves from a rating page into diligence.
The rating was earned before the diversification arrived
The instinct is to assume that an insurer concentrated in health cannot reach the top of a regional scale, and that diversification is what gets it there. The disclosures do not support that. PureHealth's release says Moody's noted Daman's growing presence in property and casualty insurance, which is expected to diversify earnings over time. PureHealth's Q1 2026 release reported AED 21 million of initial P&C gross written premium (PureHealth Q1 2026 release).
Its H1 release reported approximately AED 83 million of P&C premium against AED 5.5 billion of gross written premium for the whole insurance vertical, up 13% year on year, on vertical revenue of AED 4.1 billion, up 10%. On our arithmetic, P&C was about 1.5% of H1 premium. The diversification Moody's referred to is prospective. The A1 rests on the business Daman already had.
Five drivers, and each one is a diligence workstream
According to PureHealth's 2 July release, Moody's highlighted Daman's leading market position, strong profitability, resilient capital adequacy, high-quality reinsurance support and liquid investment portfolio as key drivers of the rating.
The same release put the profitability evidence beside it: in Q1 2026 PureHealth's insurance business generated AED 2 billion of revenue, AED 3.8 billion of gross written premium and AED 185 million of net profit, and Daman reported AED 800 million of net profit for 2025.
On our arithmetic, Q1 net profit was a little over 9% of insurance revenue. The list matters more than the letter grade. A buyer cannot commission a rating inside a diligence window, but can test a target on the same five points using the target's own audited accounts, reinsurance treaties and investment schedules, and can ask the seller to show where the target falls short of the insurer the market now treats as the reference.
For a TPA or managed-care target, the rating sits on the payer
A third-party administrator or managed-care company that carries no underwriting risk of its own will never hold an IFSR. Its revenue, though, is paid by insurers, and an IFSR is by definition an opinion of whether an insurer pays policyholder claims and obligations on time. Where a TPA's fee income comes from insurers, the credit quality of its largest payers is part of what the buyer acquires. The public reference for what the strongest of those payers looks like now carries a name and a date.
What the rating does not do
It does not price anything. An IFSR says nothing about a multiple, a cost of equity or the value of a minority stake, and it sits on one regulated entity inside a listed group reporting across its Care and Cover verticals. Using Daman's A1 as a pricing comp for a private insurer is the wrong use of it. Using it as the standard against which a target's capital, reinsurance and liquidity are measured is the right one.
Four questions before pricing a UAE health insurance target
- If the seller describes the target as strongly rated, which agency, which entity and which rating, and how far below Daman's A1 does it sit on the same scale?
- On capital adequacy, reinsurance support and investment liquidity, what do the target's audited accounts, treaty schedule and portfolio breakdown show, driver by driver, against the five Moody's named for Daman?
- Who are the reinsurers on the target's panel, and what are their current ratings as published by the agency rather than as quoted in the information memorandum?
- For a TPA or managed-care target, what share of revenue comes from each insurer, and what is each of those payers' published financial strength rating?
The Monday work is finite. Pull the target's latest audited financial statements, reinsurance treaty schedule and investment portfolio breakdown, and lay each against the five drivers Moody's named for Daman. List every reinsurer on the panel with its current rating, read at the agency rather than in the seller's deck.
For a TPA or managed-care target, rank payers by share of revenue and check each one's published financial strength rating. Keep the A1 out of the multiple and inside the diligence scope. That valuation work is where our business valuation practice begins.
Subscribe
The UAE healthcare regulatory briefing
What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.
One email a fortnight. Unsubscribe from any of them.